Akari Therapeutics PLC (ADR) - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
AKTX Nasdaq 8731 http://akaritx.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Akari Therapeutics PLC (ADR)

Akari Therapeutics to Present at Biotech Showcase™ 2023 - Jan 4th, 2023 1:00 pm
Akari Therapeutics to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech/Diagnostic Conference - Dec 1st, 2022 1:00 pm
Akari Therapeutics to Participate in the Ophthalmology Day at BTIG - Nov 22nd, 2022 1:00 pm
Akari Therapeutics Granted FDA Rare Pediatric Disease Designation of Nomacopan for the Treatment of Pediatric HSCT-TMA - Nov 10th, 2022 1:00 pm
Akari Therapeutics to Participate in the Jefferies London Healthcare Conference - Nov 9th, 2022 1:00 pm
Sidoti's November Micro-Cap Virtual Conference - Nov 8th, 2022 8:40 pm
Akari Therapeutics Announces the Appointment of John F. Neylan, III, MD as Executive Vice President, Chief Medical Officer - Nov 8th, 2022 1:00 pm
Akari Therapeutics to Participate in the Sidoti November 2022 Virtual Micro-Cap Conference - Oct 31st, 2022 12:00 pm
Akari Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification - Oct 28th, 2022 8:30 pm
Akari Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Pipeline Progress - Sep 27th, 2022 12:00 pm
Akari Therapeutics to Participate in the Cantor Oncology & HemOnc Conference - Sep 22nd, 2022 12:00 pm
Akari Therapeutics Announces $12.75 Million Registered Direct Offering - Sep 12th, 2022 12:00 pm
One Akari Therapeutics, Plc (NASDAQ:AKTX) insider upped their stake by 180% in the previous year - Sep 8th, 2022 10:48 am
Akari Therapeutics Narrows Pipeline Focus - Aug 1st, 2022 12:00 pm
Will Akari Therapeutics (NASDAQ:AKTX) Spend Its Cash Wisely? - Jul 29th, 2022 1:36 pm
Akari Therapeutics Announces Positive Results from Recent Pre-Clinical Studies of Investigational PASylated® Nomacopan That Support the Potential to Advance Research Toward IND/IMPD for Clinical Trials in Geographic Atrophy - Jul 28th, 2022 12:00 pm
Akari Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Pipeline Progress - Jul 20th, 2022 10:00 am
Akari Therapeutics Announces First Patient to Complete Course of Treatment in the Phase III Part A Clinical Trial of Investigational Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) - Jul 7th, 2022 12:00 pm
Akari Therapeutics Announces the Appointment of Accomplished Biotech Executive Melissa Bradford-Klug as Chief Operating Officer to Lead Business Development and Company Growth Strategies - Jun 13th, 2022 11:00 am
Akari Therapeutics Presents Results from the CASCADE and CORONET Studies in COVID-19 at the American Thoracic Society (ATS) 2022 Annual Meeting - May 19th, 2022 8:05 pm